AMBODRYL Drug Patent Profile
✉ Email this page to a colleague
When do Ambodryl patents expire, and when can generic versions of Ambodryl launch?
Ambodryl is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in AMBODRYL is bromodiphenhydramine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the bromodiphenhydramine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMBODRYL?
- What are the global sales for AMBODRYL?
- What is Average Wholesale Price for AMBODRYL?
Summary for AMBODRYL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Patent Applications: | 89 |
| DailyMed Link: | AMBODRYL at DailyMed |
US Patents and Regulatory Information for AMBODRYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | AMBODRYL | bromodiphenhydramine hydrochloride | CAPSULE;ORAL | 007984-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
